Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome Induced by COVID-19

Summary

Single blind randomized clinical trial designed to evaluate the efficacy of the combination of hydroxychloroquine and dexamethasone as treatment for severe Acute Respiratory Distress Syndrome (ARDS) related to coronavirus disease 19 (COVID-19). We hypothesize that dexamethasone (20 mg for 5 days followed by 10 mg for 5 days) combined with 600 mg per day dose of hydroxychloroquine for 10 days will reduce the 28-day mortality compared to hydroxychloroquine alone in patients with severe ARDS related COVID-19.

Timeline

Start

2020-04-17

Primary completion

2020-08-07

Completion

2020-08-07

Drugs

Indications